​
​

GreenLight Biosciences (GRNA) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

GRNA Stock Forecast

GreenLight Biosciences stock forecast is as follows: an average price target of $11.00 (represents a 3572.79% upside from GRNA’s last price of $0.30) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

GRNA Price Target

The average price target for GreenLight Biosciences (GRNA) is $11.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $4.00. This represents a potential 3572.79% upside from GRNA's last price of $0.30.

GRNA Analyst Ratings

Buy

According to 1 Wall Street analysts, GreenLight Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for GRNA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

GreenLight Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2022-Canaccord Genuity$4.00$1.18238.98%1235.56%
May 06, 2022-Needham$18.00$9.00100.00%5910.02%
Row per page
Go to

The latest GreenLight Biosciences stock forecast, released on Dec 08, 2022 by Canaccord Genuity company, set a price target of $4.00, which represents a 238.98% increase from the stock price at the time of the forecast ($1.18), and a 1235.56% increase from GRNA last price ($0.30).

GreenLight Biosciences Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.30$0.30$0.30
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of GreenLight Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GreenLight Biosciences's last price of $0.30. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 08, 2022Canaccord Genuity-BuyInitialise
Row per page
Go to

GreenLight Biosciences's last stock rating was published by Canaccord Genuity on Dec 08, 2022. The company Initialise its GRNA rating from "null" to "Buy".

GreenLight Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GRNAGreenLight Biosciences$0.30$11.003566.67%Buy
BWVOnconetix$0.18$4.002122.22%Buy
LGVNLongeveron$1.85$10.00440.54%Buy
CVKDCadrenal Therapeutics$15.13$32.00111.50%Buy
FHTXFoghorn Therapeutics$7.80$16.33109.36%Buy

GRNA Forecast FAQ

Is GreenLight Biosciences a good buy?

Yes, according to 1 Wall Street analysts, GreenLight Biosciences (GRNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of GRNA's total ratings.

What is GRNA's price target?

GreenLight Biosciences (GRNA) average price target is $11 with a range of $4 to $18, implying a 3572.79% from its last price of $0.299. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will GreenLight Biosciences stock go up soon?

According to Wall Street analysts' prediction for GRNA stock, the company can go up by 3572.79% (from the last price of $0.299 to the average price target of $11), up by 5910.02% based on the highest stock price target, and up by 1235.56% based on the lowest stock price target.

Can GreenLight Biosciences stock reach $0?

GRNA's average twelve months analyst stock price target of $11 supports the claim that GreenLight Biosciences can reach $0 in the near future.